SCHEMBL691826

SCHEMBL691826

[CH2]CCOCC(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8694378 0.84
SCHEMBL9122483 0.82 EPHX2 (0.40)
SCHEMBL45305 0.82 TSHR (0.47)
SCHEMBL27233283 0.81 TSHR (0.38)
SCHEMBL9123930 0.80 CES2 (0.42)
SCHEMBL5075002 0.80 CES2 (0.42)
SCHEMBL25377946 0.79 TSHR (0.45)
SCHEMBL81956 0.79 HSD17B10 (0.46)
SCHEMBL20534906 0.79 HSD17B10 (0.46)
SCHEMBL6666413 0.79 HSD17B10 (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 513 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062753-A1 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2020-02-27 US claimed
US-10428069-B2 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2019-10-01 US claimed
EP-3114128-B1 NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2019-01-02 EP claimed
US-20180370969-A1 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2018-12-27 US claimed
US-10081627-B2 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2018-09-25 US claimed
EP-3114128-A1 NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2017-01-11 EP claimed
US-20160083383-A1 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2016-03-24 US claimed
US-9233978-B2 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2016-01-12 US claimed
WO-2015132276-A1 NOVEL 6-FUSED HETEROARYLDIHYDROPYRIMIDINES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2015-09-11 WO claimed
US-20150252057-A1 Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection HOFFMANN-LA ROCHE INC. (US) 2015-09-10 US claimed
US-8242097-B2 Cosmetic use of polysaccharide compounds containing non-polymer siloxane graft(s) L'OREAL S.A. (FR) 2012-08-14 US claimed
EP-1347780-B1 COMPOSITIONS OF N-(METHYLETHYLAMINOCARBONYL)-4-(3-METHYLPHENYLAMINO)-3-PYRIDYLSULFONAMIDE AND CYCLIC OLIGOSACCHARIDES PLIVA PHARM & CHEM WORKS (HR) 2007-01-03 EP claimed
US-7037928-B2 Compositions of N-(methylethylaminocarbonyl)-4-(-3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosaccharides PLIVA, FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO (HR) 2006-05-02 US claimed
JP-2004513155-A 2004-04-30 JP claimed
US-20040039204-A1 Compositions of n-(methylethaylaminocarbonyl)-4-(-3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosacccharides PLIVA FARMACEUTSKA INDUSTRIJ, DIONICKO DRUSTVO (HR) 2004-02-26 US claimed
EP-1347780-A1 COMPOSITIONS OF N-(METHYLETHYLAMINOCARBONYL)-4-(3-METHYLPHENYLAMINO)-3-PYRIDYLSULFONAMIDE AND CYCLIC OLIGOSACCHARIDES Pliva, Farmaceutska, Industrija, Dionicko Drustvo (HR) 2003-10-01 EP claimed
WO-2002038186-A1 COMPOSITIONS OF N-(METHYLETHYLAMINOCARBONYL)-4-(3-METHYLPHENYLAMINO)-3-PYRIDYLSULFONAMIDE AND CYCLIC OLIGOSACCHARIDES PLIVA, FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO (HR) 2002-05-16 WO claimed
WO-1998035677-A1 NON-SEDATING HISTAMINE ANTAGONIST COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF BRIDGE PHARMA, INC. (US) 1998-08-20 WO claimed
EP-4387629-A1 6-SUBSTITUTED- AND 6,7-DISUBSTITUTED-7-DEAZAPURINE RIBONUCLEOSIDE ANALOGUES Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2024-06-26 EP disclosed
EP-0421823-A2 Novel tetracyclic compounds having anti-allergic and anti-asthmatic activities, their preparation and use Sankyo Company Limited (JP) 1991-04-10 EP disclosed